Evidence map›Paper›PMID 41853219›Full record

ArticleESMO real world data and digital oncology2026

Prompting large language models and evaluating inter- and intra-rater agreement for cancer progression assessment from radiology reports.

T Ó Kristjánsson, A F Henriksen, M L Hansen, D G Kovacs, A Bjerrum

Abstract read
In one paragraph

Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

T Ó KristjánssonRigshospitalet, Copenhagen, Denmark.
A F HenriksenRigshospitalet, Copenhagen, Denmark.
M L HansenRigshospitalet, Copenhagen, Denmark.
D G KovacsRigshospitalet, Copenhagen, Denmark.
A BjerrumRigshospitalet, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Manual annotation of free-text radiology reports is time-consuming and costly, delaying real-world evidence (RWE) studies in oncology. This study aimed to evaluate the performance of large language models (LLMs) in annotating cancer progression from Danish free-text radiology reports. The objectives were to determine whether human-to-LLM inter-rater agreement was non-inferior to human-to-human agreement, establish human intra-rater agreement, and develop a framework for tuning LLM performance to RWE needs. Materials and methods: We identified 376 radiology reports from 184 patients with metastatic breast cancer from Danish electronic health records. Six human annotators, including two experts, classified radiology reports as progressive disease (PD) or non-PD. A 'reverse questioning' strategy was used to evaluate five LLM model series (Mistral, Gemma, Gemma 2, Llama 3, and Llama 3.1). Bootstrapping estimated confidence intervals (CIs) and assessed non-inferiority of the best-performing LLM ensemble compared with human agreement, using a non-inferiority margin of 0.1. Results: The LLM framework was non-inferior to human annotators with a mean Cohen's kappa of 0.82 (95% CI 0.74-0.89) for human-to-LLM versus 0.79 (95% CI 0.71-0.86) for human-to-human agreement ( Conclusions: The proposed LLM framework was non-inferior to human annotators in classifying cancer progression from free-text radiology reports. This offers significant potential for using LLMs as a tool for identifying tumor progression events in clinical assessment and research.

Indexed as

electronic health recordfree-text reportsinter-rater agreementintra-rater agreementlarge language modeloncologyreal-world evidence

Identifiers

PMID41853219
PMCPMC12993880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.